Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

BACKGROUND: The rationale for the evaluation of trametinib in advanced biliary cancer (BC) is based on the presence of mitogen-activated protein kinase alterations and on earlier promising results with MEK inhibitors in BC. METHODS: Patients with histologically proven BC who progressed on gemcitabin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Cancer
Main Authors: Kim, Richard D., McDonough, Shannon, El-Khoueiry, Anthony B., Bekaii-Saab, Tanios S., Stein, Stacey M., Sahai, Vaibhav, Keogh, George P., Kim, Edward J., Baron, Ari D., Siegel, Abby B., Barzi, Afsaneh, Guthrie, Katherine A., Javle, Milind, Hochster, Howard
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539324/
https://ncbi.nlm.nih.gov/pubmed/32234665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.01.026
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares